MMV253   Click here for help

GtoPdb Ligand ID: 10024

Synonyms: AZ13721412
Antimalarial Ligand
Compound class: Synthetic organic
Comment: MMV253 is the preclinical candidate for the triaminopyrimidines (TAPs), a novel class of antimalarial compounds identified from a phenotypic screen [1].

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 87.03
Molecular weight 465.28
XLogP 3.98
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC1CN(CCN1C)c1cnc(nc1Nc1cc(n(n1)C)C)Nc1nc(C)c(c(c1)C1CC1)F
Isomeric SMILES C[C@@H]1CN(CCN1C)c1cnc(nc1Nc1cc(n(n1)C)C)Nc1nc(C)c(c(c1)C1CC1)F
InChI InChI=1S/C24H32FN9/c1-14-10-21(31-33(14)5)28-23-19(34-9-8-32(4)15(2)13-34)12-26-24(30-23)29-20-11-18(17-6-7-17)22(25)16(3)27-20/h10-12,15,17H,6-9,13H2,1-5H3,(H2,26,27,28,29,30,31)/t15-/m1/s1
Guide to Malaria Pharmacology Comments
MMV253 is being developed as part of a single-exposure radical cure.
It is compound 13 in patent WO2015165660 [2].

Potential Target/Mechanism Of Action: Evidence from genetic experiments indicates that subunit D of Plasmodium V-type proton ATPase (PfV-type proton ATPase) may be a possible molecular target [1].
Target Candidate Profiles
Profile Intended Use Target Stage Comment References
TCP-1 reduce parasite burden asexual blood stages